Industry
Biotechnology
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Loading...
Open
7.01
Mkt cap
227M
Volume
166K
High
7.27
P/E Ratio
-0.54
52-wk high
22.33
Low
6.78
Div yield
N/A
52-wk low
5.77
Portfolio Pulse from
November 13, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:42 am
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 5:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 3:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 7:25 pm
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 11:38 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:22 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 4:44 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.